StockCIK 2035832
Aktis Oncology, Inc. (AKTS): Insider Trades and Fund Holdings
In the past 12 months, Aktis Oncology, Inc. insiders reported 0 open-market purchases worth $0 and 1 sale worth $259K; 1 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$259KSold by insiders, 12 months
2Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 24, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 24 | Akos CzibereChief Medical Officer | ▼ SELL10b5-1 | $259K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Akos Czibere | Chief Medical Officer | 0 | $0 | 1 | $259K |
ADVERTISEMENT
320 × 100 ad slot
Tracked funds that report AKTS
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Soros Fund Management | 100,000 | $3.22M | No change |
| Renaissance Technologies | 95,400 | $3.07M | ▲ New |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →